Navigation Links
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Date:5/30/2009

r lymph nodes, around half of patients can survive for five years or more. However, few lung cancers are found at this early stage and it is normally diagnosed at the advanced stage, when five year survival falls to approximately 15%(6).

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com.

The statements contained herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of the preparation of this press release and the Company undertakes no obligation to update these forward-looking statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those risk factors identified in the Company's Annual Report/Form 20-F for 2008. Nothing contained herein should be construed as a profit forecast.

Reference List

(1) Herbst, R. et al. Vandetanib plus docetaxel vs docetaxel as 2nd-line treatment for patients with advanced non-small-cell lung c
'/>"/>

SOURCE AstraZeneca Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
2. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
3. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
4. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
5. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
6. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
7. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
8. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
11. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ONTOWN, N.J., Nov. 5 Ost...rging field of biologic products for regenerative ...third quarter ended September 30, 2009. ,, "Dur...e release of our three new biologic products Magn...ogy and Plexur M® Innovative Grafting," said ...
(Date:11/5/2009)...NT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall/... ), a specialty pharmaceutical company focused on ...ry products that address important therapeutic nee...t will host a webcast and teleconference with mana...ults on Thursday, November 12, 2009, at 5:00 p.m. ...
(Date:11/5/2009)...NA, Minn., Nov. 5 ARKRAY, Inc., th...f-monitoring systems, today announced that it has ...g Administration for its new GLUCOCARD Vital blood...d strip platform, which ARKRAY will make available...o be a significant complement to the existing GLUC...
Breaking Medicine Technology:Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Tummy troubles gastrin key in bacterial induced stomach cancer 8978 1Tummy troubles gastrin key in bacterial induced stomach cancer 8978 2BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 1BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 2BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 3BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 4OPTIFAST 28R 29 Program Pleases Patients With Innovative Tasty Full Meal Replacement Bars 49839 1OPTIFAST 28R 29 Program Pleases Patients With Innovative Tasty Full Meal Replacement Bars 49839 2
(Date:11/8/2009)... , A jury of 8 people in ...te County woman $2,300,000 in pain and suffering f...renney, James Tallman and Alicia Nocera of Thomas ... behalf of the plaintiff, Vita Monestersky and aga...e an emergency total abdominal hysterectomy at age...
(Date:11/8/2009)... , WASHINGTON, Nov. 8 /PRNewswire-USNewswire/...merica (PhRMA) Senior Vice President Ken Johnson r...e health care reform bill: ,, "We are disappoin...iness echoed by millions of hardworking Americans ...House of Representatives who voted against the bil...
(Date:11/8/2009)... , AARP Praises House Passage of Health Care...rengthen Medicare, improve coverage for all Americ...e/ -- SUMMARY: Tonight the United States House o...rm legislation that would strengthen Medicare for ...ies that prices millions of Americans out of affor...
(Date:11/7/2009)... , HOUSTON, Nov. 7 ...esented Lisa James, Director of Health at the Fami... Distinguished Service today at its semi-annual po...ed Service is the highest honor the AMA House of D...: http://www.newscom.com/cgi-bin/prnh/20081209/...
(Date:11/7/2009)... , Brown: "Faithful Catholics have a respon...re, not negotiate the status quo." ,, WASHING... Life League president Judie Brown released the fo... Rigali will support Speaker Nancy Pelosi,s Afford...ided an amendment preserving the status quo for ab...
Breaking Medicine News(10 mins):Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors Family Violence Prevention Expert 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2
...i-thymocyte globulin (ATG), a compound made from r...tine steroids in reducing rejection of transplante...g to Dr. James Eason of the Ochsner Multi-Organ Tr...er rejection and severity rates than patients who ...
...eam of researchers who reviewed medical literature...out with a startling expose!!!! Nearly 80% of p...in actually are under the misconception that they ...School of Medicine, say that many patients fail to...
...emergency medicine expert said in New York on Thur...efing on heart disease, that rapidly cooling peopl...e a way to bring them back to life without organ d... due to sudden cardiac arrest, which is a differen...
...ologists have warned that the common white patches... many cases. A simple genetic test can help pinpoi...Scientists at the University of Oslo spearheaded t...er of chromosomes in the cells that make up the pa...
...earchers in four countries have unanimously opined...V) Epidemic did not arise from an oral polio vacci...gesting the contrary have no scientific evidence t...itute in Philadelphia, Pennsylvania, from lingerin...
... Directorate of Anti-dumping and Allied Duties, un...ommended provisional anti-dumping duties on parace...stigation against imports of the commonly used dru...Labs, and Vijayawada-based Srinivasa Agro Industri...
Other Medicine News:Health News:ATG useful in transplant patients as substitute for steroids 2Health News:Patients often assume wrongly that they are allergic to penicillin 2
...AREDS formula is the one and only vitamin and mine...nstitute's age-related eye study (AREDS) 10-year t...cal Age-Related Eye Disease Study (AREDS) by the N...Institutes of Health) showed that a unique vitamin...
Ocuvite® Eye Vitamins and Mineral Supplement
...aps, the patented next-generation dietary suppleme...systemically address the root inflammatory cause a... peer-reviewed literature that these specific nutr...ther affected parts of the body, such as mucous me...
...the industry-leading portal to QC information, pro... way to access their quality control data and othe...b enables Bio-Rad customers to access on-demand (I...s, as well as convenient online data entry and man...
Medicine Products: